CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals today announced that it will host a key opinion leader (KOL) webinar to discuss the unmet medical need in migraine management and the potential role for rofecoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment landscape on Tuesday, October 25, 2022, at 11:00 AM Eastern Time. A live Q&A session will follow the formal presentation.
CARLSBAD, Calif.--(BUSINESS WIRE)--BriOri BioTech, an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications, announces its patent for “Topical Compositions Containing Rofecoxib (Vioxx) and Methods of Making and Using the Same” was issued on March 1, 2022. This patent covers a reformulation of Vioxx, a COX-2 specific NSAID, from an oral to topical formulation with the intention of alleviating osteoarthritis related pain of the knee and joint pain, and reducing the need for opioids in certain patient populations. With the global market for topical pain relief treatments estimated to be $8.8 billion in 2019 and projected to grow to $12.2 billion by 2027, BriOri BioTech aims to bring a safer and more effective solution to the market to meet a large unmet need.
CARLSBAD, Calif.--(BUSINESS WIRE)--BriOri BioTech, an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications, announces it has received a March 1, 2022, patent issue notification for “Topical Compositions Containing Rofecoxib and Methods of Making and Using the Same.” This patent covers a reformulation of rofecoxib, a COX-2 specific NSAID, from an oral to topical formulation with the intention of alleviating osteoarthritis related pain of the knee and joint pain, and reducing the need for opioids in certain patient populations. With the global market for topical pain relief treatments estimated to be $8.8 billion in 2019 and projected to grow to $12.2 billion by 2027, BriOri BioTech aims to bring a safer and more effective solution to the market to meet a large unmet need.
CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals will present three abstracts highlighting the need for new non-opioid treatment options for bleeding disorder patients during the 63rd American Society of Hematology Annual Meeting and Exposition in Atlanta. The Massachusetts-based pharmaceutical company is focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.
The voluntary withdrawal of rofecoxib (Vioxx) from the market in September 2004 marked the end of a controversial era for a once highly profitable and widely used drug. It also marked the beginning of years of high-profile product-liability litigation that would cost Merck billions.
Patients take a doctor's prescription, believing that their doctor knows best, and the vast majority of the time that is correct. So it can be quite a shock when a recall happens on well-known prescription drugs because of possible health issues. Zantac, a popular protein pump inhibitor that treats extreme cases of heartburn or recurring acid reflux, was recently added to the list of products getting pulled off the shelf.
Privately-held Tremeau Pharmaceuticals is moving its generic version of Vioxx into Phase III trials for the treatment of hemophilic arthropathy, a degenerative joint disease occurring in patients with hemophilia.
Today and tomorrow, the FDA is convening a panel of experts to give it advice on what kinds of studies it should require to determine whether diabetes drugs help the heart, or hurt it. The current FDA requirement, that companies first prove that a new medicine does not create excess harm for the heart and then conduct a study to see if the medicine prevents heart attacks and other heart problems, dates back to a period a decade ago when a series of controversies about unsafe medicines made national headlines.
Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs), particularly diclofenac and ibuprofen, has been linked with an increased risk of cardiac arrest in research published in European Heart Journal - Cardiovascular Pharmacotherapy.
Pfizer CEO Ian Read, for his part, also touted job growth. “I think we can be a very positive part of the story of creating jobs in the United States if we get the tax reform,” Read said during the company's Q4 earnings call. Read did not attend the meeting because of the earnings release.